Paris is emerging as a focal point for Europe’s next phase in oncology, as science, capital and industry converge at Campus Grand Parc.

WHO is sponsoring a trial testing drugs for Bundibugyo virus, while adding the first Ebola diagnostic test to its emergency use list.

The UK-US pharmaceuticals deal could cost the National Health Service (NHS) around £45bn ($60bn) within a decade and divert resources away from essential services, an analysis has suggested. The UK ...

SK bioscience is set to lead the Gates Foundation-funded ROTOR project, an AI-based platform aimed at reducing uncertainty in vaccine-development decisions.

The EC has granted approval for Novartis’ Itvisma as a treatment for children two years and older, teenagers, and adults who have 5q SMA with a bi-allelic mutation in the SMN1 gene.

The industry looks set to continue a preference for European outsourcing facilities as national tax systems exert influence.

Ipsen’s Memo acquisition is the second the former has signed this week alone, following its blockbuster Kartos buyout on 29 June.

Children as young as two with either sickle cell disease or thalassemia are now eligible for the gene therapy.

The US FDA has declined to approve Unicycive Therapeutics’ resubmitted NDA for OLC to treat hyperphosphatemia in CKD patients on dialysis.

Our editorial team delve into the key takeaways from the 2026 HLTH Europe conference and the 2026 BIO International Convention.

Anthropic launches Claude Science as big tech companies increasingly eye expansion in the wider healthcare and life sciences space.

AbbVie presented new results from the Phase III ECLIPSE trial (NCT06241313) at this year's Congress of the European Academy of Neurology (EAN).